\
&
Contact us
\
&
Contact us
The administrative and financial framework with rules for application and project implementation of Horizon 2020 call are set-out in the Grant Agreement; the Annotated Model Grant Agreement explains extensively all details.
The European commission gives on a regular basis trainings with background information on coordinators' days, that can be followed live or through webstreaming. Presentations can be consulted in the documents in below.
Information on specific legal and financial topics are listed and documented in the documents in below.
ann.vanhauwaert@fwo.be
+32 2 550 15 60
Ria.debreucker@vlaio.be
+32 2 553 13 77
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
